UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

DNA demethylating agent 5‐azacytidine inhibits myeloid‐derived suppressor cells induced by tumor growth and cyclophosphamide treatment

Journal of leukocyte biology, 2014-05, Vol.95 (5), p.743-753

2014

Volltextzugriff (PDF)

Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors

Journal of immunotherapy (1997), 2012-06, Vol.35 (5), p.374-384

2012

Volltextzugriff (PDF)

Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy

International journal of oncology, 2016-03, Vol.48 (3), p.953-964

2016

Volltextzugriff (PDF)

Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes

Oncotarget, 2014-08, Vol.5 (16), p.6923-6935

2014

Volltextzugriff (PDF)

Therapy for minimal residual tumor disease: β‐Galactosylceramide inhibits the growth of recurrent HPV16‐associated neoplasms after surgery and chemotherapy

International journal of cancer, 2010-06, Vol.126 (12), p.2997-3004

2010

Volltextzugriff (PDF)

Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours

Immunology, 2008-02, Vol.123 (2), p.218-227

2008

Volltextzugriff (PDF)

Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I‐deficient and ‐proficient HPV16‐associated tumours

International journal of cancer, 2006-04, Vol.118 (7), p.1836-1842

2006

Volltextzugriff (PDF)

Assessment of sclerocorneal incision architecture after phacoemulsification using AS-OCT

Scripta scientifica medica, 2018-12, Vol.50 (4), p.17

2018

Volltextzugriff (PDF)

NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours

Oncology reports, 2011-01, Vol.25 (1), p.281-288

2011

Volltextzugriff (PDF)

Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines

Oncotarget, 2016-08, Vol.7 (34), p.54952-54964

2016

Volltextzugriff (PDF)

Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine

Oncology reports, 2011-06, Vol.25 (6), p.1683-1689

2011

Volltextzugriff (PDF)

Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model

Immunobiology (1979), 2013-06, Vol.218 (6), p.851-859

2013

Volltextzugriff (PDF)

Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16

Vaccine, 2003-02, Vol.21 (9), p.891-896

2003

Volltextzugriff (PDF)

Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines

International journal of oncology, 2010-03, Vol.36 (3), p.545-551

2010

Volltextzugriff (PDF)

CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours

International journal of oncology, 2007-05, Vol.30 (5), p.1247-1251

2007

Volltextzugriff (PDF)

Therapy for minimal residual tumor disease: b-Galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy

International journal of cancer, 2010-06, Vol.126 (12), p.2997-3004

2010

Volltextzugriff (PDF)

Minimal residual disease as the target for immunotherapy and gene therapy of cancer (review)

Oncology reports, 2005-11, Vol.14 (5), p.1377

2005

Volltextzugriff (PDF)

Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF

International journal of oncology, 2004-01, Vol.24 (1), p.161

2004

Volltextzugriff (PDF)

Depletion of Treg cells inhibits minimal residual disease after surgery of HPV16-associated tumours

International journal of oncology, 2006-12, Vol.29 (6), p.1567-1571

2006

Volltextzugriff (PDF)

Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours

International journal of oncology, 2007-04, Vol.30 (4), p.1011-1017

2007

Volltextzugriff (PDF)

Administration of anti-CD25 mAb leads to impaired [alpha]-galactosylceramide-mediated induction of IFN-[gamma] production in a murine model

Immunobiology (1979), 2013-06, Vol.218 (6), p.851-859

2013

Volltextzugriff (PDF)

HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines

International journal of oncology, 2004-10, Vol.25 (4), p.1165

2004

Volltextzugriff (PDF)

Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines

International journal of oncology, 2003-03, Vol.22 (3), p.691

2003

Volltextzugriff (PDF)

Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin

International journal of oncology, 2002-03, Vol.20 (3), p.643

2002

Volltextzugriff (PDF)

New fibrillin gene mutation - possible cause of ascending aortic dilation in patients with aortic valve disease: Preliminary results

The International journal of angiology, 2009-06, Vol.18 (2), p.99-102

2009

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(61)
Tagungsberichte
(1)

Sprache

Englisch
(61)
Slowakisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

DNA demethylating agent 5‐azacytidine inhibits myeloid‐derived suppressor cells induced by tumor growth and cyclophosphamide treatment

Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors

Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy

Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes

Therapy for minimal residual tumor disease: β‐Galactosylceramide inhibits the growth of recurrent HPV16‐associated neoplasms after surgery and chemotherapy

Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours

Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I‐deficient and ‐proficient HPV16‐associated tumours

Assessment of sclerocorneal incision architecture after phacoemulsification using AS-OCT

NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours

Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines

Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine

Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model

Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16

Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines

CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours

Therapy for minimal residual tumor disease: b-Galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy

Minimal residual disease as the target for immunotherapy and gene therapy of cancer (review)

Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF

Depletion of Treg cells inhibits minimal residual disease after surgery of HPV16-associated tumours

Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours

Administration of anti-CD25 mAb leads to impaired [alpha]-galactosylceramide-mediated induction of IFN-[gamma] production in a murine model

HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines

Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines

Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin

New fibrillin gene mutation - possible cause of ascending aortic dilation in patients with aortic valve disease: Preliminary results

Suchergebnisse filtern